mibiotico - mibiotico

RECOMENDACIONES DE PROBIÓTICOS SEGÚN SU APLICACIÓN

Una herramienta práctica para ayudar en la toma de decisiones clínicas sobre la terapia probiótica adecuada para usted o sus pacientes

Esta Guía Clínica está diseñada para traducir la evidencia científica disponible para los productos probióticos en información práctica y clínicamente relevante. Está pensada para ser utilizada como una herramienta de toma de decisiones clínicas, permitiendo a los médicos seleccionar fácilmente el producto, la dosis y la formulación adecuados para una indicación específica.

En la actualidad, el conjunto de pruebas de las intervenciones probióticas está creciendo junto con la demanda popular de estos productos. Hay pruebas que apoyan el uso de productos probióticos para una variedad de indicaciones más allá de la salud intestinal, sin embargo, las aplicaciones y los resultados son específicos de las cepas.

Debido a los frecuentes cambios en la disponibilidad comercial de las cepas probióticas, a las nuevas pruebas publicadas y a la creciente investigación, desde 2008 se ha realizado una revisión y actualización anual de esta Guía Clínica. La ausencia generalizada de efectos adversos atribuibles a los probióticos apoya el uso generalizado de estos productos, pero se recomienda una investigación continua.

Se realizó una revisión sistemática de la literatura utilizando criterios de inclusión predefinidos para identificar estudios de resultados clínicos definidos para cepa(s) probiótica(s) específica(s). Se identificaron los productos disponibles en el mercado que contenían dicha(s) cepa(s) y se utilizaron los niveles de evidencia para calificar la fuerza del beneficio esperado. Esta información se recopiló en un formato de tabla. Los datos fueron evaluados por un grupo de revisores expertos independientes.

En el caso de los probióticos, las pruebas clínicas deben vincularse a formulaciones específicas definidas por el género, la especie, la designación alfanumérica o la cepa, el número de bacterias vivas presentes, la mezcla de cepas probióticas presentes y, por último, los ingredientes no activos presentes.

El autor y los revisores hicieron todo lo posible por incluir los datos clínicos publicados de las formulaciones probióticas disponibles. Para evitar el sesgo de selección hacia alguna formulación específica, hemos realizado una búsqueda bibliográfica en dos bases de datos (PubMed, EMBASE) y hemos contactado con nuestros expertos independientes para identificar cualquier estudio publicado o no publicado.

Nuestro objetivo es garantizar que se seleccione el producto/la cepa adecuados para el resultado deseado. Esta Guía Clínica no debe interpretarse como una revisión sistemática, ni como una «guía de práctica clínica», ni tampoco como un aval para que las empresas comercialicen declaraciones de propiedades saludables.

Se recomienda encarecidamente a los lectores que revisen por sí mismos las pruebas enumeradas para cada producto. Consulte las publicaciones individuales para conocer los detalles de las poblaciones de pacientes estudiadas (por ejemplo, edad, sexo, comorbilidades) y los detalles del efecto clínico (significación estadística, tamaño del efecto del tratamiento, precisión de los intervalos de confianza).

Para que un producto figure en esta guía clínica deben cumplirse todos los criterios de inclusión que se indican a continuación:

Disponible comercialmente en Canadá (o en Estados Unidos) como suplemento o alimento que contiene probióticos
Estado generalmente reconocido como seguro (FDA) y/o número de producto natural (Health Canada) para la(s) cepa(s) probiótica(s) utilizada(s) en los productos
Pruebas clínicas publicadas favorables para la(s) cepa(s) particular(es) presente(s) en cada producto
En el caso de los productos que contengan múltiples cepas, la evidencia debe ser para la combinación especificada y NO extrapolada de la evidencia para las cepas probióticas por separado

Nota: Algunos productos están excluidos de la edición actual debido a los cambios en las cepas utilizadas

Perla clínica: Las indicaciones de uso se basan en cepas o combinaciones específicas estudiadas conjuntamente

Precaución: No está permitida la extrapolación de los datos actuales ni las recomendaciones a aplicar para diferentes combinaciones de cepas probióticas.

Principales productos probióticos respaldados con evidencia científica

❄ – El producto requiere refrigeración

🍀 – Alimentos funcionales

🌾 – Sin gluten

Activia®

Marca Comercial:

Activia® 🍀 ❄

Cepa probiótica

B. (animalis) lactis CNCM I-2494

Aplicaciones (nivel de recomendación)

E – Estreñimiento (I)
SII – Síndrome del intestino irritable (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Ferm. milk lq.

CFU/Dosis

1B/porción

Nº de Dosis/Dia

1-3 porciones

Tienda Online

Enlace directo de compra a terceros

Align®

Marca Comercial:

Align® 🌾

Cepa probiótica

B. longum 35624

Aplicaciones (nivel de recomendación)

SII – Síndrome del intestino irritable (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Cápsulas

CFU/Dosis

1B/cápsula

Nº de Dosis/Dia

1 cápsula

Tienda Online

Enlace directo de compra a terceros

Align® Chewables 🌾

Marca Comercial:

Align® Chewables 🌾

Cepa probiótica

B. longum 35624

Aplicaciones (nivel de recomendación)

SII – Síndrome del intestino irritable (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Tableta

CFU/Dosis

1B/tableta

Nº de Dosis/Dia

1 tableta

Tienda Online

Enlace directo de compra a terceros

Bio-K+® Antibio Pro

Marca Comercial:

Bio-K+® Antibio Pro ❄ 🌾

Cepa probiótica

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

Aplicaciones (nivel de recomendación)

DAA – Diarrea asociada a los antibióticos – Prevención (I)
DACD – Diarrea asociada a Clostridium difícil – Prevención (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Cápsula

CFU/Dosis

50B/cápsula

Nº de Dosis/Dia

1-2 cápsulas

Tienda Online

Enlace directo de compra a terceros

Bio-K+® BiomePRO Drinkable Probiotic

Marca Comercial:

Bio-K+® BiomePRO Drinkable Probiotic ❄ 🌾

Cepa probiótica

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

Aplicaciones (nivel de recomendación)

DAA – Diarrea asociada a los antibióticos – Prevención (I)🍁
CDAD – Diarrea asociada a Clostridium difficile – Prevención(I)🍁
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADA

Forma de dosificación

Ferm. rice lq.

CFU/Dosis

100B/botella

Nº de Dosis/Dia

0.5-1 botella

Tienda Online

Enlace directo de compra a terceros

Bio-K+® Drinkable Probiotics

Marca Comercial:

Bio-K+® Drinkable Probiotics ❄ 🌾

Cepa probiótica

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMEDADO

Forma de dosificación

Ferm. milk lq.
Ferm. vegan. lq.

CFU/Dosis

50B/bottle
50B/bottle

Nº de Dosis/Dia

1 bottle
1 bottle

Tienda Online

Enlace directo de compra a terceros

Bio-K+® IBS Pro

Marca Comercial:

Bio-K+® IBS Pro ❄ 🌾

Cepa probiótica

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

Aplicaciones (nivel de recomendación)

IBS – Síndrome del intestino irritable (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Capsula

CFU/Dosis

50B/Capsula

Nº de Dosis/Dia

2 Capsulas

Tienda Online

Enlace directo de compra a terceros

BioGaia® ProTectis® Baby Drops

Marca Comercial:

BioGaia® ProTectis® Baby Drops 🌾

Cepa probiótica

L. reuteri DSM 17938

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (II)
C – Estreñimiento (I)
HP – Helicobacter pylori – Adjunct to standard eradication therapy (I)
ID – Infectious diarrhea (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Drops

CFU/Dosis

100M/5drops

Nº de Dosis/Dia

5 drops

Tienda Online

Enlace directo de compra a terceros

BioGaia® ProTectis® Baby Drops with Vitamin D

Marca Comercial:

BioGaia® ProTectis® Baby Drops with Vitamin D 🌾

Cepa probiótica

L. reuteri DSM 17938

Aplicaciones (nivel de recomendación)

Forma de dosificación

Drops

CFU/Dosis

100M/5drops

Nº de Dosis/Dia

5 drops

Tienda Online

Enlace directo de compra a terceros

BioGaia® ProTectis® Chew tabs 🌾

Marca Comercial:

BioGaia® ProTectis® Chew tabs 🌾

Cepa probiótica

L. reuteri DSM 17938

Aplicaciones (nivel de recomendación)

Forma de dosificación

Chewable tablet

CFU/Dosis

100M/tablet

Nº de Dosis/Dia

1 tablet

Tienda Online

Enlace directo de compra a terceros

BioGaia® Junior Probiotic Tablets with Vitamin D

Marca Comercial:

BioGaia® Junior Probiotic Tablets with Vitamin D 🌾

Cepa probiótica

L. reuteri DSM 17938

Aplicaciones (nivel de recomendación)

Forma de dosificación

Chewable tablet

CFU/Dosis

100M/tablet

Nº de Dosis/Dia

1 tablet

Tienda Online

Enlace directo de compra a terceros

BioGaia® ProDentis™

Marca Comercial:

BioGaia® ProDentis™

Cepa probiótica

L. reuteri ATCC PTA 5289
L. reuteri DSM 17938

Aplicaciones (nivel de recomendación)

OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Lozenge

CFU/Dosis

200M/lozenge

Nº de Dosis/Dia

1 lozenge

Tienda Online

Enlace directo de compra a terceros

Biomed Bacillus Coagulans

Marca Comercial:

Biomed Bacillus Coagulans

Cepa probiótica

Bacillus coagulans MTCC 5856

Aplicaciones (nivel de recomendación)

IBS – Síndrome del intestino irritable (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Capsula

CFU/Dosis

1B/Capsula

Nº de Dosis/Dia

2 Capsula

Tienda Online

Enlace directo de compra a terceros

Calm Biotic®

Marca Comercial:

Calm Biotic®

Cepa probiótica

B. longum R0175
L. helveticus R0052

Aplicaciones (nivel de recomendación)

M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Capsula

CFU/Dosis

3B/Capsula

Nº de Dosis/Dia

1 Capsula

Tienda Online

Enlace directo de compra a terceros

CulturedCare® Probiotic Gum with BLIS K12®

Marca Comercial:

CulturedCare® Probiotic Gum with BLIS K12® 🌾

Cepa probiótica

Streptococcus salivarius K12

Aplicaciones (nivel de recomendación)

OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Lozenge

CFU/Dosis

0.5B/lozenge

Nº de Dosis/Dia

2-10 lozenges

Tienda Online

Enlace directo de compra a terceros

Culturelle® Digestive Daily Probiotic Chewables

Marca Comercial:

Culturelle® Digestive Daily Probiotic Chewables 🌾

Cepa probiótica

L. rhamnosus GG

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III)
HP – Helicobacter pylori – Adjunct to standard eradication therapy (I)
IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II)
TD – Traveler’s diarrhea prevention (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Chewable tablet

CFU/Dosis

10B/tablet

Nº de Dosis/Dia

1 tablet

Tienda Online

Enlace directo de compra a terceros

Culturelle® Digestive Health Daily Probiotic Capsules

Marca Comercial:

Culturelle® Digestive Health Daily Probiotic Capsules 🌾

Cepa probiótica

L. rhamnosus GG

Aplicaciones (nivel de recomendación)

Forma de dosificación

Capsula

CFU/Dosis

10B/Capsula

Nº de Dosis/Dia

1 Capsula

Tienda Online

Enlace directo de compra a terceros

DanActive®

Marca Comercial:

DanActive® 🍀 ❄

Cepa probiótica

L. casei sp. Paracasei CNCM I-1518

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (I)
CID – Common infectious disease – community acquired (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Ferm. milk lq.

CFU/Dosis

10B/serving

Nº de Dosis/Dia

1-2 servings

Tienda Online

Enlace directo de compra a terceros

Digestive Care™ 10 Billion Daily Probiotic

Marca Comercial:

Digestive Care™ 10 Billion Daily Probiotic

Cepa probiótica

L. plantarum 299v

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (III)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III)
IBS – Síndrome del intestino irritable (I)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Capsula

CFU/Dosis

10B/Capsula

Nº de Dosis/Dia

1-2 Capsula

Tienda Online

Enlace directo de compra a terceros

FlorastorMax®

Marca Comercial:

FlorastorMax® 🌾

Cepa probiótica

Saccharomyces boulardii lyo CNCM I-745

Aplicaciones (nivel de recomendación)

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)
HP – Helicobacter pylori – Adjunct to standard eradication therapy (I)
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III)
TD – Traveler’s diarrhea prevention (I)
Referencias Científicas
Opinión de Mibiotico: NO RECOMENDADO

Forma de dosificación

Sachet

CFU/Dosis

10B/sachet

Nº de Dosis/Dia

1 sachet

Tienda Online

Enlace directo de compra a terceros

Florastor®

Marca Comercial:

Florastor® 🌾

Cepa probiótica

Saccharomyces boulardii lyo CNCM I-745

Aplicaciones (nivel de recomendación)

Forma de dosificación

Capsula
Sachet

CFU/Dosis

5B/Capsula
5B/sachet

Nº de Dosis/Dia

1-2 Capsulas
1-2 sachets

Tienda Online

Enlace directo de compra a terceros

Genestra Brands HMF Metabolic

Marca Comercial:

Genestra Brands HMF Metabolic ❄ 🌾

Cepa probiótica

L. acidophilus CUL-60
L. acidophilus CUL-21
L. plantarum CUL-66
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

Aplicaciones (nivel de recomendación)

WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Capsula

CFU/Dosis

50B/Capsula

Nº de Dosis/Dia

1 Capsula

Tienda Online

Enlace directo de compra a terceros

Marca Comercial:

XXX

Cepa probiótica

Aplicaciones (nivel de recomendación)

Opinión de Mibiotico:

Forma de dosificación

CFU/Dosis

Nº de Dosis/Dia

Tienda Online

Enlace directo de compra a terceros

Genestra Brands® HMF Forte

Marca Comercial:

Genestra Brands® HMF Forte ❄ 🌾

Cepa probiótica

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

Aplicaciones (nivel de recomendación)

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)
Referencias Científicas
Opinión de Mibiotico: RECOMENDACIÓN MEDIA

Forma de dosificación

Capsula

CFU/Dosis

10B/Capsula

Nº de Dosis/Dia

2-3 Capsulas

Tienda Online

Enlace directo de compra a terceros

Tienda Online	Marca Comercial:	Cepa probiótica	Aplicaciones (nivel de recomendación)	Forma de dosificación	CFU/Dosis	Nº de Dosis/Dia
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎
🔎	Genestra Brands® HMF IBS Relief ❄ 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Capsula	25B/Capsula	1 Capsula
🔎	Genestra Brands® HMF Intensive ❄ 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Capsula	25B/Capsula	Capsula
🔎	Genestra Brands® HMF Intensive 50 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Capsula	50B/Capsula	1 Capsula
🔎	Genestra Brands® HMF Intensive Powder ❄ 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Powder	25B/1 scoop (1 gram)	1 scoop
🔎	Genestra Brands® HMF Super Powder ❄ 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Powder	10B/1 scoop (1 gram)	2-3 scoops
🔎	GoodBelly® Probiotic Juice Drinks 🍀	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I) Referencias Científicas	Liquid	20B/serving (8 oz)	1 serving
🔎	Materna® Opti-Lac®	L. fermentum LC40™ CECT5716	Mastitis – Mastitis en madres lactantes (tratamiento y prevención) (I) Referencias Científicas	Capsula	3B/Capsula	1 Capsula
🔎	Mutaflor® ❄	Echerichia coli Nissle 1917	IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) Referencias Científicas	Capsula	2.5-25B/Capsula	1-2 Capsulas
🔎	Pregnancy Care Probiotic 🌾	L. rhamnosus R0011 L.helveticus R0052	IBS – Síndrome del intestino irritable (III) Referencias Científicas	Capsula	2B/Capsula	1-2 Capsulas
🔎	Probiotic Sticks	B. longum R0175 L. helveticus R0052	M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II) Referencias Científicas	Stick	3B/stick	1 stick
🔎	Ultra Probiotic Complex by GNC 🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. bifidum CUL-20 B. lactis CUL-34	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II) Referencias Científicas	Packet Capsula	25B/packet 25B/ 50B/ 75B per Capsula	1-2 packets 1-2 Capsula
🔎	UltraFlora® Control 🌾	B. animalis ssp. lactis 420 (B420™)	WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (I) Referencias Científicas	Capsula	10B/Capsula	1 Capsula
🔎	UltraFlora® Balance	L. acidophilus NCFM® B. lactis Bi-07®	IBS – Síndrome del intestino irritable (II) Referencias Científicas	Capsula	15B/Capsula	2 Capsulas
🔎	UltraFlora® Cold Support 🌾	L plantarum HEAL9 L. paracasei 8700:2	CID – Common infectious disease – community acquired (I) Referencias Científicas	Capsula	1B/Capsula	1 Capsula
🔎	UltraFlora® Intensive Care 🌾	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I) Referencias Científicas	Capsula	10B/Capsula	2 Capsulas
🔎	UltraFlora® Restore 🌾	B. lactis Bi-07® L. acidophilus NCFM® B. lactis Bl-04 L. paracasei Lpc-37	AAD – Diarrea asociada a antibióticos – Prevención (I) Referencias Científicas	Capsula	20B/Capsula	1 Capsula
🔎	Visbiome® ❄ 🌾 This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen	L. acidophilus DSM24735/SD5212 L. paracasei DSM24733/SD5218 L. delbrueckii subsp. bulgaricus DSM24734/SD5210 L. plantarum DSM24730/SD5209 B. longum DSM24736/SD5220 B. infantis DSM24737/SD5219 B. breve DSM24732/SD5206 S. thermophilus DSM24731/SD5207	C – Estreñimiento (II) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I) Referencias Científicas	Sachet	450B/sachet	1-4 sachets
🔎	Yakult 🍀 ❄	L.casei Shirota	C – Estreñimiento (I) CID – Common infectious disease – community acquired (I) M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II) Referencias Científicas	Bottle	8B/bottle (80ml)	1-2 bottles

Recomendaciones según su aplicación práctica

DAA – Diarrea asociada a los antibióticos- Prevención

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & No of Doses/Day
Bio-K+® Antibio Pro❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Capsula	50B/Capsula	1-2 Capsulas
Bio-K+® BiomePRO Drinkable Probiotic❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Ferm. rice lq.	100B/bottle	0.5-1 bottle
Bio-K+® Drinkable Probiotics❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Ferm. vegan. lq. Ferm. milk lq.	50B/bottle 50B/bottle	1 bottle 1 bottle
BioGaia® ProTectis® Baby Drops🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Baby Drops with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Chew tabs🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
BioGaia® Junior Probiotic Tablets with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
Culturelle® Digestive Daily Probiotic Chewables🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Chewable tablet	10B/tablet	1 tablet
Culturelle® Digestive Health Daily Probiotic Capsules🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Capsula	10B/Capsula	1 Capsula
DanActive®🍀❄	L. casei sp. Paracasei CNCM I-1518	AAD – Diarrea asociada a antibióticos – Prevención (I) CID – Common infectious disease – community acquired (I)	Ferm. milk lq.	10B/serving	1-2 servings
Digestive Care™ 10 Billion Daily Probiotic	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	1-2 Capsula
FlorastorMax®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet	10B/sachet	1 sachet
Florastor®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Capsula Sachet	5B/Capsula 5B/sachet	1-2 Capsula 1-2 sachets
GoodBelly® Probiotic Juice Drinks🍀	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Liquid	20B/serving (8 oz)	1 serving
UltraFlora® Intensive Care🌾	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	2 Capsula
UltraFlora® Restore🌾	B. lactis Bi-07® L. acidophilus NCFM® B. lactis Bl-04 L. paracasei Lpc-37	AAD – Diarrea asociada a antibióticos – Prevención (I)	Capsula	20B/Capsula	1 Capsula

C – Estreñimiento

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & No of Doses/Day
Activia®🍀❄	B. (animalis) lactis CNCM I-2494	C – Estreñimiento (I) IBS – Síndrome del intestino irritable (I)	Ferm. milk lq.	1B/serving	1-3 servings
BioGaia® ProTectis® Baby Drops🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Baby Drops with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Chew tabs🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
BioGaia® Junior Probiotic Tablets with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
Visbiome®❄🌾 This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen	L. acidophilus DSM24735/SD5212 L. paracasei DSM24733/SD5218 L. delbrueckii subsp. bulgaricus DSM24734/SD5210 L. plantarum DSM24730/SD5209 B. longum DSM24736/SD5220 B. infantis DSM24737/SD5219 B. breve DSM24732/SD5206 S. thermophilus DSM24731/SD5207	C – Estreñimiento (II) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I)	Sachet	450B/sachet	1-4 sachets
Yakult🍀❄	L.casei Shirota	C – Estreñimiento (I) CID – Common infectious disease – community acquired (I) M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)	Bottle	8B/bottle (80ml)	1-2 bottles

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose	No of Doses/Day
Bio-K+® Antibio Pro❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Capsula	50B/Capsula	1-2 Capsula
Bio-K+® BiomePRO Drinkable Probiotic❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Ferm. rice lq.	100B/bottle	0.5-1 bottle
Bio-K+® Drinkable Probiotics❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)	Ferm. vegan. lq. Ferm. milk lq.	50B/bottle 50B/bottle	1 bottle 1 bottle
Culturelle® Digestive Daily Probiotic Chewables🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Chewable tablet	10B/tablet	1 tablet
Culturelle® Digestive Health Daily Probiotic Capsules🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Capsula	10B/Capsula	1 Capsula
Digestive Care™ 10 Billion Daily Probiotic	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	1-2 Capsula
FlorastorMax®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet	10B/sachet	1 sachet
Florastor®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet Capsula	5B/sachet 5B/Capsula	1-2 sachets 1-2 Capsula
Genestra Brands® HMF Forte❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	10B/Capsula	2-3 Capsula
Genestra Brands® HMF IBS Relief❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	25B/Capsula	1 Capsula
Genestra Brands® HMF Intensive❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	25B/Capsula	1 Capsula
Genestra Brands® HMF Intensive 50🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	50B/Capsula	1 Capsula
Genestra Brands® HMF Intensive Powder❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Powder	25B/1 scoop (1 gram)	1 scoop
Genestra Brands® HMF Super Powder❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Powder	10B/1 scoop (1 gram)	2-3 scoops
GoodBelly® Probiotic Juice Drinks🍀	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Liquid	20B/serving (8 oz)	1 serving
Ultra Probiotic Complex by GNC🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. bifidum CUL-20 B. lactis CUL-34	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula Packet	25B/ 50B/ 75B per Capsula 25B/packet	1-2 Capsula 1-2 packets
UltraFlora® Intensive Care🌾	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	2 Capsula

CID – Common infectious disease – community acquired

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & No of Doses/Day
DanActive®🍀❄	L. casei sp. Paracasei CNCM I-1518	AAD – Diarrea asociada a antibióticos – Prevención (I) CID – Common infectious disease – community acquired (I)	Ferm. milk lq.	10B/serving	1-2 servings
UltraFlora® Cold Support🌾	L plantarum HEAL9 L. paracasei 8700:2	CID – Common infectious disease – community acquired (I)	Capsula	1B/Capsula	1 Capsula
Yakult🍀❄	L.casei Shirota	C – Estreñimiento (I) CID – Common infectious disease – community acquired (I) M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)	Bottle	8B/bottle (80ml)	1-2 bottles

HP – Helicobacter pylori – Adjunct to standard eradication therapy

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & Nº of Doses/Day
BioGaia® ProTectis® Baby Drops🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Baby Drops with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Chew tabs🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
BioGaia® Junior Probiotic Tablets with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
Culturelle® Digestive Daily Probiotic Chewables🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Chewable tablet	10B/tablet	1 tablet
Culturelle® Digestive Health Daily Probiotic Capsules🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Capsula	10B/Capsula	1 Capsula
FlorastorMax®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet	10B/sachet	1 sachet
Florastor®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Capsula Sachet	5B/Capsula 5B/sachet	1-2 Capsula 1-2 sachets

IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & No of Doses/Day
Culturelle® Digestive Daily Probiotic Chewables🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Chewable tablet	10B/tablet	1 tablet
Culturelle® Digestive Health Daily Probiotic Capsules🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Capsula	10B/Capsula	1 Capsula
Visbiome®❄🌾 This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen	L. acidophilus DSM24735/SD5212 L. paracasei DSM24733/SD5218 L. delbrueckii subsp. bulgaricus DSM24734/SD5210 L. plantarum DSM24730/SD5209 B. longum DSM24736/SD5220 B. infantis DSM24737/SD5219 B. breve DSM24732/SD5206 S. thermophilus DSM24731/SD5207	C – Estreñimiento (II) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I)	Sachet	450B/sachet	1-4 sachets

IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar

Brand Name	Probiotic Strain	Applications (Level of Recommendation)	Dosage Form	CFU/Dose & No of Doses/Day
FlorastorMax®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet	10B/sachet	1 sachet
Florastor®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet Capsula	5B/sachet 5B/Capsula	1-2 sachets 1-2 Capsula
Mutaflor®❄	Echerichia coli Nissle 1917	IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I)	Capsula	2.5-25B/Capsula	1-2 Capsula
Visbiome®❄🌾 This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen	L. acidophilus DSM24735/SD5212 L. paracasei DSM24733/SD5218 L. delbrueckii subsp. bulgaricus DSM24734/SD5210 L. plantarum DSM24730/SD5209 B. longum DSM24736/SD5220 B. infantis DSM24737/SD5219 B. breve DSM24732/SD5206 S. thermophilus DSM24731/SD5207	C – Estreñimiento (II) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I)	Sachet	450B/sachet	1-4 sachets

IBS – Síndrome del intestino irritable

Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose & No of Doses/Day
Activia®🍀❄	B. (animalis) lactis CNCM I-2494	C – Estreñimiento (I) IBS – Síndrome del intestino irritable (I)	Ferm. milk lq.	1B/serving	1-3 servings
Align®🌾	B. longum 35624	IBS – Síndrome del intestino irritable (I)	Capsula	1B/Capsula	1 Capsula
Align® Chewables🌾	B. longum 35624	IBS – Síndrome del intestino irritable (I)	Tablet	1B/tablet	1 tablet
Bio-K+® IBS Pro❄🌾	L. acidophilus CL1285 L. casei LBC80R L. rhamnosus CLR2	IBS – Síndrome del intestino irritable (I)	Capsula	50B/Capsula	2 Capsula
Biomed Bacillus Coagulans	Bacillus coagulans MTCC 5856	IBS – Síndrome del intestino irritable (II)	Capsula	1B/Capsula	2 Capsula
Digestive Care™ 10 Billion Daily Probiotic	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	1-2 Capsula
Genestra Brands® HMF Forte❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	10B/Capsula	2-3 Capsula
Genestra Brands® HMF IBS Relief❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	25B/Capsula	1 Capsula
Genestra Brands® HMF Intensive❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	25B/Capsula	1 Capsula
Genestra Brands® HMF Intensive 50🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula	50B/Capsula	1 Capsula
Genestra Brands® HMF Intensive Powder❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Powder	25B/1 scoop (1 gram)	1 scoop
Genestra Brands® HMF Super Powder❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Powder	10B/1 scoop (1 gram)	2-3 scoops
GoodBelly® Probiotic Juice Drinks🍀	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Liquid	20B/serving (8 oz)	1 serving
Pregnancy Care Probiotic🌾	L. rhamnosus R0011 L.helveticus R0052	IBS – Síndrome del intestino irritable (III)	Capsula	2B/Capsula	1-2 Capsula
Ultra Probiotic Complex by GNC🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 B. bifidum CUL-20 B. lactis CUL-34	CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II) IBS – Síndrome del intestino irritable (II)	Capsula Packet	25B/ 50B/ 75B por Capsula 25B/packet	1-2 Capsula 1-2 packets
UltraFlora® Balance	L. acidophilus NCFM® B. lactis Bi-07®	IBS – Síndrome del intestino irritable (II)	Capsula	15B/Capsula	2 Capsula
UltraFlora® Intensive Care🌾	L. plantarum 299v	AAD – Diarrea asociada a antibióticos – Prevención (III) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) IBS – Síndrome del intestino irritable (I)	Capsula	10B/Capsula	2 Capsula

ID – Infectious diarrhea

Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	No of Doses/Day
BioGaia® ProTectis® Baby Drops🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Baby Drops with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Drops	100M/5drops	5 drops
BioGaia® ProTectis® Chew tabs🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet
BioGaia® Junior Probiotic Tablets with Vitamin D🌾	L. reuteri DSM 17938	AAD – Diarrea asociada a antibióticos – Prevención (II) C – Estreñimiento (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) ID – Infectious diarrhea (II)	Chewable tablet	100M/tablet	1 tablet

LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population

.	Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose & No of Doses/Day
	Visbiome®❄🌾 This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen	L. acidophilus DSM24735/SD5212 L. paracasei DSM24733/SD5218 L. delbrueckii subsp. bulgaricus DSM24734/SD5210 L. plantarum DSM24730/SD5209 B. longum DSM24736/SD5220 B. infantis DSM24737/SD5219 B. breve DSM24732/SD5206 S. thermophilus DSM24731/SD5207	C – Estreñimiento (II) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I) LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I)	Sachet	450B/sachet	1-4 sachets

M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment)

Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose & No of Doses/Day
Calm Biotic®	B. longum R0175 L. helveticus R0052	M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)	Capsula	3B/Capsula	1 Capsula
Probiotic Sticks	B. longum R0175 L. helveticus R0052	M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)	Stick	3B/stick	1 stick
Yakult🍀❄	L.casei Shirota	C – Estreñimiento (I) CID – Common infectious disease – community acquired (I) M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)	Bottle	8B/bottle (80ml)	1-2 bottles

Mastitis – Mastitis en madres lactantes (tratamiento y prevención)

	Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose& No of Doses/Day
	Materna® Opti-Lac®	L. fermentum LC40™ CECT5716	Mastitis – Mastitis en madres lactantes (tratamiento y prevención) (I)	Capsula	3B/Capsula	1 Capsula

OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries)

	Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose& No of Doses/Day
	BioGaia® ProDentis™	L. reuteri ATCC PTA 5289 L. reuteri DSM 17938	OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (I)	Lozenge	200M/lozenge	1 lozenge
	CulturedCare® Probiotic Gum with BLIS K12®🌾	Streptococcus salivarius K12	OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (II)	Lozenge	0.5B/lozenge	2-10 lozenges

TD – Traveler’s diarrhea prevention

Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose & No of Doses/Day
Culturelle® Digestive Daily Probiotic Chewables🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Chewable tablet	10B/tablet	1 tablet
Culturelle® Digestive Health Daily Probiotic Capsules🌾	L. rhamnosus GG	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (II) TD – Traveler’s diarrhea prevention (II)	Capsula	10B/Capsula	1 Capsula
FlorastorMax®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet	10B/sachet	1 sachet
Florastor®🌾	Saccharomyces boulardii lyo CNCM I-745	AAD – Diarrea asociada a antibióticos – Prevención (I) CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I) HP – Helicobacter pylori – Adjunct to standard eradication therapy (I) IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (III) TD – Traveler’s diarrhea prevention (I)	Sachet Capsula	5B/sachet 5B/Capsula	1-2 sachets 1-2 Capsula

WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference)

.	Brand Name	Probiotic Strain	Nivel de recomendación y aplicaciones	Dosage Form	CFU/Dose & No of Doses/Day
	Genestra Brands HMF Metabolic❄🌾	L. acidophilus CUL-60 L. acidophilus CUL-21 L. plantarum CUL-66 B. animalis subsp. lactis CUL-34 B. bifidum CUL-20	WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (II)	Capsula	50B/Capsula	1 Capsula
	UltraFlora® Control🌾	B. animalis ssp. lactis 420 (B420™)	WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (I)	Capsula	10B/Capsula	1 Capsula

Listado completo de referencias científicas

Nivel de recomendación*

Nivel I

Evidencia obtenida de al menos un ensayo diseñado adecuadamente (por ejemplo, aleatorización, cegamiento, comparaciones poblacionales apropiadas) con un cálculo de potencia para el/los resultado/s de interés. El comité de revisión de expertos se reserva el derecho de tomar la decisión final sobre el nivel de recomendación.
(NIVEL MÁS ALTO)

Nivel II

Evidencia obtenida de ensayos controlados bien diseñados sin aleatorización; evidencia obtenida de ensayos aleatorizados que no satisfacen todos los criterios enumerados en el Nivel I. Evidencia obtenida de estudios analíticos de cohortes o de casos y controles bien diseñados, preferiblemente de más de un centro o grupo de investigación. Evidencia obtenida de múltiples series temporales con o sin la intervención. Los resultados dramáticos en ensayos no controlados también podrían considerarse como este tipo de evidencia.

Nivel III

Opiniones de autoridades respetadas, basadas en la experiencia clínica, estudios descriptivos o informes de comités de expertos.

Activia®

Activia®
🍀 ❄

B. (animalis) lactis CNCM I-2494

C – Estreñimiento (I)
IBS – Síndrome del intestino irritable (I)

Ferm. milk lq.

1B/serving

1-3 servings

Aplicación	Nivel	Referencias
C – Estreñimiento	I	177. Yang, Y.X., M. He, G. Hu, J. Wei, P. Pages, X.H. Yang, and S. Bourdu-Naturel. «Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women.» World J Gastroenterol 14.40 (2008): 6237-6243.
IBS – Síndrome del intestino irritable	I	175. Agrawal, A., Lesley A. Houghton, J. Morris, B. Reilly, D. Guyonnet, N. Goupil Feuillerat, A. Schlumberger, S. Jakob, and P. J. Whorwell. «Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.» Alimentary pharmacology & therapeutics 29.1 (2009): 104-114. 176. Guyonnet, D., O. Chassany, P. Ducrotte, C. Picard, M. Mouret, C‐H. Mercier, and C. Matuchansky. «Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial.» Alimentary pharmacology & therapeutics 26.3 (2007): 475-486.

Align®

Align®
🌾

B. longum 35624

IBS – Síndrome del intestino irritable (I)

Capsula

1B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	I	1. Brenner, DM, and WD Chey. «Bifidobacterium Infantis 35624: A Novel Probiotic for the Treatment of IBS.» Reviews in Gastroenterological Disorders 9.1 (2009): 7-15. 2. Quigley, EM, PJ Whorwell, L. Altringer, J. Morel, L. O’Mahony, and F. Shanahan. «Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium Infantis 35624.» American Journal of Gastroenterology 100.S9 (2005): S326. 3. Whorwell, P., L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O’Mahony, B. Kiely, F. Shanahan, and EM Quigley. «Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome.» American Journal of Gastroenterology 101 (2006): 1581-590. 4. O’Mahony, L., J. Mccarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O’Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. M. Quigley. «Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles.» Gastroenterology 128.3 (2005): 541-51.

Align® Chewables

Align® Chewables
🌾

B. longum 35624

IBS – Síndrome del intestino irritable (I)

Tablet

1B/tablet

1 tablet

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	I	1. Brenner, DM, and WD Chey. «Bifidobacterium Infantis 35624: A Novel Probiotic for the Treatment of IBS.» Reviews in Gastroenterological Disorders 9.1 (2009): 7-15. 2. Quigley, EM, PJ Whorwell, L. Altringer, J. Morel, L. O’Mahony, and F. Shanahan. «Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium Infantis 35624.» American Journal of Gastroenterology 100.S9 (2005): S326. 3. Whorwell, P., L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O’Mahony, B. Kiely, F. Shanahan, and EM Quigley. «Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome.» American Journal of Gastroenterology 101 (2006): 1581-590. 4. O’Mahony, L., J. Mccarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O’Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. M. Quigley. «Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles.» Gastroenterology 128.3 (2005): 541-51.

Bio-K+® Antibio Pro

Bio-K+® Antibio Pro
❄ 🌾

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)

Capsula

50B/Capsula

1-2 Capsula

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	5. Beausoleil, M., N. Fortier, S. Guenette, A. L’Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. «Effect of a Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Caseiin the Prevención of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial.» Canadian Journal of Gastroenterology 21.11 (2007): 732-36. 6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	I	6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64. 8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. «Probiotics for the Prevención of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.» Annals of Internal Medicine 157.12 (2012): 878 9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. «Is Primary Prevención of Clostridium Difficile Infection Possible with Specific Probiotics?» International Journal of Infectious Diseases 6.11 (2012): E786-792. 10. McFarland, L.V., N. Ship, J. Auclair and M. Millette. «Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence » Journal of Hospital Infection 99.4 (2018):443-452.

Bio-K+ ® BiomePRO Drinkable Probiotic

Bio-K+ ® BiomePRO Drinkable Probiotic
❄ 🌾

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)

Ferm. rice lq.

100B/bottle

0.5-1 bottle

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	5. Beausoleil, M., N. Fortier, S. Guenette, A. L’Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. «Effect of a Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Caseiin the Prevención of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial.» Canadian Journal of Gastroenterology 21.11 (2007): 732-36. 6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	I	6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64. 8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. «Probiotics for the Prevención of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.» Annals of Internal Medicine 157.12 (2012): 878 9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. «Is Primary Prevención of Clostridium Difficile Infection Possible with Specific Probiotics?» International Journal of Infectious Diseases 6.11 (2012): E786-792. 10. McFarland, L.V., N. Ship, J. Auclair and M. Millette. «Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence » Journal of Hospital Infection 99.4 (2018):443-452.

Bio-K+® Drinkable Probiotics

Bio-K+® Drinkable Probiotics❄🌾

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

AAD – Diarrea asociada a antibióticos – Prevención (I)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (I)

Ferm. milk lq.
Ferm. vegan. lq.

50B/bottle
50B/bottle

1 bottle
1 bottle

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	5. Beausoleil, M., N. Fortier, S. Guenette, A. L’Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. «Effect of a Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Caseiin the Prevención of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial.» Canadian Journal of Gastroenterology 21.11 (2007): 732-36. 6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	I	6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. «Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients.» American Journal of Gastroenterology 105.7 (2010): 1636-641. 7. Sampalis, J., E. Psaradellis, and E. Rampakakis. “Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study.” Archives of Medical Science: AMS 6.1 (2010): 56–64. 8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. «Probiotics for the Prevención of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.» Annals of Internal Medicine 157.12 (2012): 878 9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. «Is Primary Prevención of Clostridium Difficile Infection Possible with Specific Probiotics?» International Journal of Infectious Diseases 6.11 (2012): E786-792. 10. McFarland, L.V., N. Ship, J. Auclair and M. Millette. «Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence » Journal of Hospital Infection 99.4 (2018):443-452.

Bio-K+® IBS Pro

Bio-K+® IBS Pro
❄ 🌾

L. acidophilus CL1285
L. casei LBC80R
L. rhamnosus CLR2

IBS – Síndrome del intestino irritable (I)

Capsula

50B/Capsula

2 Capsula

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	I	18. Preston, K., R. Krumian, J. Hattner, D. de Montigny, M. Stewart and S. Gaddam. «Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study.» Beneficial Microbes 9.5 (2018): 697-706.

BioGaia® ProTectis® Baby Drops

BioGaia ® ProTectis ® Baby Drops 🌾

L. reuteri DSM 17938

Drops

100M/5drops

5 drops

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	II	12. Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. «A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevención of Antibiotic-associated Diarrhea in Hospitalized Adults.» Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
C – Estreñimiento	I	17. Ojetti, V., G. Ianiro, A. Tortora, G. D’Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. «The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Estreñimiento: A Randomized, Double-Blind, Placebo-Controlled Trial.»Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	13. Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. «Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related.» Digestive and Liver Disease 40 (2008) 14. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. «Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study.» Helicobacter 13.2 (2008): 127-34. 15. Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. «Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection–a Double-blind Randomised Placebo-controlled Cross-over Clinical Study.» Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93. 16. Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. «Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study.» Dig Liver Dis 37.Suppl 1 (2005): S88.
ID – Infectious diarrhea	II	11. Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. «Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule.» Annals of Oncology. S9 ed. Vol. 19. (2008).

BioGaia® ProTectis® Baby Drops with Vitamin D

BioGaia ® ProTectis ® Baby Drops with Vitamin D 🌾

L. reuteri DSM 17938

Drops

100M/5drops

5 drops

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	II	12. Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. «A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevención of Antibiotic-associated Diarrhea in Hospitalized Adults.» Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
C – Estreñimiento	I	17. Ojetti, V., G. Ianiro, A. Tortora, G. D’Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. «The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Estreñimiento: A Randomized, Double-Blind, Placebo-Controlled Trial.»Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	13. Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. «Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related.» Digestive and Liver Disease 40 (2008) 14. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. «Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study.» Helicobacter 13.2 (2008): 127-34. 15. Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. «Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection–a Double-blind Randomised Placebo-controlled Cross-over Clinical Study.» Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93. 16. Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. «Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study.» Dig Liver Dis 37.Suppl 1 (2005): S88.
ID – Infectious diarrhea	II	11. Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. «Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule.» Annals of Oncology. S9 ed. Vol. 19. (2008).

BioGaia® ProTectis® Chew tabs

BioGaia® ProTectis® Chew tabs 🌾

L. reuteri DSM 17938

Chewable tablet

100M/tablet

1 tablet

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	II	12. Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. «A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevención of Antibiotic-associated Diarrhea in Hospitalized Adults.» Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
C – Estreñimiento	I	17. Ojetti, V., G. Ianiro, A. Tortora, G. D’Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. «The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Estreñimiento: A Randomized, Double-Blind, Placebo-Controlled Trial.»Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	13. Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. «Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related.» Digestive and Liver Disease 40 (2008) 14. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. «Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study.» Helicobacter 13.2 (2008): 127-34. 15. Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. «Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection–a Double-blind Randomised Placebo-controlled Cross-over Clinical Study.» Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93. 16. Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. «Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study.» Dig Liver Dis 37.Suppl 1 (2005): S88.
ID – Infectious diarrhea	II	11. Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. «Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule.» Annals of Oncology. S9 ed. Vol. 19. (2008).

BioGaia® Junior Probiotic Tablets with Vitamin D

BioGaia® Junior Probiotic Tablets with Vitamin D 🌾

L. reuteri DSM 17938

Chewable tablet

100M/tablet

1 tablet

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	II	12. Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. «A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevención of Antibiotic-associated Diarrhea in Hospitalized Adults.» Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
C – Estreñimiento	I	17. Ojetti, V., G. Ianiro, A. Tortora, G. D’Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. «The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Estreñimiento: A Randomized, Double-Blind, Placebo-Controlled Trial.»Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	13. Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. «Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related.» Digestive and Liver Disease 40 (2008) 14. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. «Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study.» Helicobacter 13.2 (2008): 127-34. 15. Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. «Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection–a Double-blind Randomised Placebo-controlled Cross-over Clinical Study.» Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93. 16. Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. «Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study.» Dig Liver Dis 37.Suppl 1 (2005): S88.
ID – Infectious diarrhea	II	11. Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. «Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule.» Annals of Oncology. S9 ed. Vol. 19. (2008).

BioGaia® ProDentis™

L. reuteri ATCC PTA 5289
L. reuteri DSM 17938

OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (I)

Lozenge

200M/lozenge

1 lozenge

Aplicación	Nivel	Referencias
OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries)	I	63. Schlagenhauf U, Jakob L et al. «Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT.» J Clin Periodontol. 2016 Nov;43(11):948-954 64. Teughels W, Durukan A, et al. «Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study.» J Clin Periodontol 2013; 40: 1025–1035 65. Galofré M, Palao D, Vicario M, Nart J, Violant D. «Clinical and microbiological evaluation of the effect of Lactobacillus reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial.» J Periodontal Res. 2018 Jun;53(3):378-390. 66. Kraft-Bodi E, Jørgensen M, Keller MK. «Effect of Probiotic Bacteria on Oral Candida in Frail Elderly.» J Dent Res. 2015 Sep;94(9 Suppl):181S-6S 67. Tekce M, Ince G, Gursoy H, et al. «Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study.» J Clin Periodontol 2015; 42: 363–372

Biomed Bacillus Coagulans

Bacillus coagulans MTCC 5856

IBS – Síndrome del intestino irritable (II)

Capsula

1B/Capsula

2 Capsula

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	II	19. Majeed, Muhammed et al.: «Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.» Nutrition journal vol. 15 21. 27 Feb. 2016, doi:10.1186/s12937-016-0140-6

Calm Biotic®

B. longum R0175
L. helveticus R0052

M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)

Capsula

3B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment)	II	20. Huang R., H. Ning, L. Yang, C. Jia, F. Yang, G. Xu, and H. Tan. «Efficacy of Probiotics on Anxiety: A Meta-analysis of Randomized Controlled Trials.» Neuropsychiatry 7.6 (2017): 862-71. 21. Messaoudi M., R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel, and J. Cazaubiel. «Assessment of Psychotropic-like Properties of a Probiotic Formulation ( Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) in Rats and Human Subjects.» British Journal of Nutrition 105.05 (2010): 755-64. 22. Messaoudi M., N.Violle, J. Bisson, D. Desor, H. Javelot, and C. Rougeot. «Beneficial Psychological Effects of a Probiotic Formulation (Lactobacillus HelveticusR0052 AndBifidobacterium LongumR0175) in Healthy Human Volunteers.» Gut Microbes 2.4 (2011): 256-61.

CulturedCare® Probiotic Gum with BLIS K12®

CulturedCare® Probiotic Gum with BLIS K12® 🌾

Streptococcus salivarius K12

OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries) (II)

Lozenge

0.5B/lozenge

2-10 lozenges

Aplicación	Nivel	Referencias
OH – Oral health (reductions of tonsillitis, laryngitis, and dental caries)	II	61. Burton, J. P., C. N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg.. «A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters.» Journal of applied microbiology 100.4 (2006): 754-764. 62. Di Pierro, F, G. Donato, F. Fomia, T. Adami, D. Careddu, C. Cassandro, and R. Albera. «Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.» International journal of general medicine 5 (2012): 991.

Culturelle® Digestive Daily Probiotic Chewables

Culturelle® Digestive Daily Probiotic Chewables 🌾

L. rhamnosus GG

Chewable tablet

10B/tablet

1 tablet

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	23. Kale-Pradhan, P. B., H. K. Jassal, and S. M. Wilhelm. «Role of Lactobacillus in the Prevención of Antibiotic-Associated Diarrhea: A Meta-analysis.» Pharmacotherapy 30.2 (2010): 119-26.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	III	25. Gorbach, S. L., Chang, T. W. & Goldin, B. «Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG.» Lancet 2, 1519 (1987). 26. Bennet RG, Gorbach SL et al. «Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG» Nutr Today Suppl Vol 31 No 6 Nov/Dec 1996 27. Morrow, L. E., Kollef, M. H. & Casale, T. B. «Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.» American journal of respiratory and critical care medicine 182, 1058-1064 (2010).
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	24. Armuzzi, A., F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Anti, A. De Lorenzo, P. Pola, G. Gasbarrini, and A. Gasbarrini. «The Effect of Oral Administration of Lactobacillus GG on Antibiotic-associated Gastrointestinal Side-effects during Helicobacter Pylori Eradication Therapy.» Alimentary Pharmacology and Therapeutics 15.2 (2001): 163-69.
IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis	II	28. Gosselink MP, Schouten WR et al. «Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG» Dis Colon Rectum 2004; 47: 876-84
TD – Traveler’s diarrhea prevention	II	29. Oksanen, P.J., et al. «Prevención of travellers’ diarrhoea by Lactobacillus GG.» Annals of medicine, 1990. 22(1): p. 53-56. 30. Hilton, E., et al. «Efficacy of Lactobacillus GG as a diarrheal preventive in travelers.» Journal of travel medicine, 1997. 4(1): p. 41-43.

Culturelle® Digestive Health Daily Probiotic Capsules

Culturelle® Digestive Health Daily Probiotic Capsules 🌾

L. rhamnosus GG

Capsula

10B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I🍁	23. Kale-Pradhan, P. B., H. K. Jassal, and S. M. Wilhelm. «Role of Lactobacillus in the Prevención of Antibiotic-Associated Diarrhea: A Meta-analysis.» Pharmacotherapy 30.2 (2010): 119-26.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	III	25. Gorbach, S. L., Chang, T. W. & Goldin, B. «Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG.» Lancet 2, 1519 (1987). 26. Bennet RG, Gorbach SL et al. «Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG» Nutr Today Suppl Vol 31 No 6 Nov/Dec 1996 27. Morrow, L. E., Kollef, M. H. & Casale, T. B. «Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.» American journal of respiratory and critical care medicine 182, 1058-1064 (2010).
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	24. Armuzzi, A., F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Anti, A. De Lorenzo, P. Pola, G. Gasbarrini, and A. Gasbarrini. «The Effect of Oral Administration of Lactobacillus GG on Antibiotic-associated Gastrointestinal Side-effects during Helicobacter Pylori Eradication Therapy.» Alimentary Pharmacology and Therapeutics 15.2 (2001): 163-69.
IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis	II	28. Gosselink MP, Schouten WR et al. «Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG» Dis Colon Rectum 2004; 47: 876-84
TD – Traveler’s diarrhea prevention	II🍁	29. Oksanen, P.J., et al. «Prevención of travellers’ diarrhoea by Lactobacillus GG.» Annals of medicine, 1990. 22(1): p. 53-56. 30. Hilton, E., et al. «Efficacy of Lactobacillus GG as a diarrheal preventive in travelers.» Journal of travel medicine, 1997. 4(1): p. 41-43.

DanActive®

DanActive®
🍀 ❄

L. casei sp. Paracasei CNCM I-1518

AAD – Diarrea asociada a antibióticos – Prevención (I)
CID – Common infectious disease – community acquired (I)

Ferm. milk lq.

10B/serving

1-2 servings

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	182. Hickson, M., A.L. D’Souza, N. Muthu, T.R. Rogers, S. Want, C. Rajkumar, and C.J. Bulpitt. «Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.» Bmj 335.7610 (2007): 80. 193. Alberda C., S. Marcushamer, T. Hewer, N. Journault and D. Kutsogiannis «Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevención of Antibiotic Associated Diarrhea and Clostridium difficile.» Nutrients. 2018 May; 10(5):539
CID – Common infectious disease – community acquired	I	185. Boge, T., M. Rémigy, S. Vaudaine, J. Tanguy, R. Bourdet-Sicard, and S. Van Der Werf. «A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials.» Vaccine 27.41 (2009): 5677-5684. 186. Guillemard, E., F. Tondu, F. Lacoin, and J. Schrezenmeir. «Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial.» British journal of nutrition 103.01 (2010): 58-68. 187. Guillemard, E., J. Tanguy, A.L. Flavigny, S. de la Motte, and J. Schrezenmeir. «Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial.» Journal of the American College of Nutrition 29.5 (2010): 455-468. 188. Marcos, A., J. W., E. Nova, S. Gómez, A. Alvarez, R. Alvarez, J.A. Mateos, and J.M. Cobo. «The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress.» European journal of nutrition 43.6 (2004): 381-389. 189. Meyer, A.L., M. Micksche, I. Herbacek, and I. Elmadfa. «Daily intake of probiotic as well as conventional yogurt has a stimulating effect on cellular immunity in young healthy women.» Annals of nutrition and metabolism 50.3 (2006): 282-289. 190. Ortiz-Andrellucchi, A., A. Sánchez-Villegas, C. Rodríguez-Gallego, A. Lemes, T. Molero, A. Soria, L. Pena-Quintana, M. Santana, O. Ramírez, J. García, and F. Cabrera. «Immunomodulatory effects of the intake of fermented milk with Lactobacillus casei DN114001 in lactating mothers and their children.» British journal of nutrition 100.04 (2008): 834-845. 191. Tiollier, E., M. Chennaoui, D. Gomez-Merino, C. Drogou, E. Filaire, and C.Y. Guezennec. «Effect of a probiotics supplementation on respiratory infections and immune and hormonal parameters during intense military training.» Military medicine 172.9 (2007): 1006-1011. 192. Turchet, P., M. Laurenzano, S. Auboiron, and J. M. Antoine. «Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study.» The journal of nutrition, health & aging 7.2 (2002): 75-77.

Digestive Care™ 10 Billion Daily Probiotic

L. plantarum 299v

AAD – Diarrea asociada a antibióticos – Prevención (III)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III)
IBS – Síndrome del intestino irritable (I)

Capsula

10B/Capsula

1-2 Capsula

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	III	31. Lonnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. «Intake of Lactobacillus Plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics.» Journal of Clinical Gastroenterology 44.2 (2010): 106-12.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	III	32. Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. «Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics.» Acta Anaesthesiologica Scandinavica 52.8 (2008): 1096-102. 36. Kujawa-Szewieczek, A.; Adamczak, M.; Kwiecień, K.; Dudzicz, S.; Gazda, M.; Więcek, A. «The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics.» Nutrients 2015, 7, 10179-10188
IBS – Síndrome del intestino irritable	I	33. Niedzielin, K., H. Kordecki, and B. Birkenfeld. «A Controlled, Double-blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome.» European Journal of Gastroenterology and Hepatology 13.10 (2001): 1143-147. 34. Nobaek, S., M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. «Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome.» The American Journal of Gastroenterology 95.5 (2000): 1231-238. 35. Ducrotte, P., P. D. Sawant, and V. Jayanthi. «Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome.» World Journal of Gastroenterology 18.30 (2012): 4012-018.

FlorastorMax®

FlorastorMax®
🌾

Saccharomyces boulardii lyo CNCM I-745

Sachet

10B/sachet

1 sachet

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	37. Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. «Prophylactic Saccharomyces Boulardii in the Prevención of Antibiotic-associated Diarrhea: A Prospective Study.» Medical Science Monitor 12.4 (2006): PI19-22. 38. Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. «The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of HighâDose Vancomycin Combined WithSaccharomyces Boulardii.» Clinical Infectious Diseases 31.4 (2000): 1012-017.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	I	8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. «Probiotics for the Prevención of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.» Annals of Internal Medicine 157.12 (2012): 878 9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. «Is Primary Prevención of Clostridium Difficile Infection Possible with Specific Probiotics?» International Journal of Infectious Diseases 6.11 (2012): E786-792. 38. Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. «The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of HighâDose Vancomycin Combined WithSaccharomyces Boulardii.» Clinical Infectious Diseases 31.4 (2000): 1012-017. 39. Mcfarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. «A Randomized Placebo-controlled Trial of Saccharomyces Boulardii in Combination with Standard Antibiotics for Clostridium Difficile Disease.» JAMA: The Journal of the American Medical Association 271.24 (1994): 1913-918. 51. Flatley EA, Wilde AM, Nailor MD. «Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.» J Gastrointestin Liver Dis. 2015;24(1):21–24
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	44. Song, M. J., D.I Park, J.H. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, and B.I. Kim. «The Effect of Probiotics and Mucoprotective Agents on PPI‐Based Triple Therapy for Eradication of Helicobacter pylori.» Helicobacter 15.3 (2010): 206-213. 45. Szajewska, H., A. Horvath, and A. Piwowarczyk. «Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment.» Alimentary pharmacology & therapeutics 32.9 (2010): 1069-1079. 46. Cindoruk, M., G. Erkan,T. Karakan, A. Dursun, and S. Unal. «Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study.» Helicobacter 12.4 (2007): 309-316.
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar	III	43. Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. «Saccharomyces boulardii in maintenance treatment of Crohn’s disease.» Digestive diseases and sciences 45.7 (2000): 1462-1464. 47. Guslandi, M., Giollo, P., and Testoni, P. «(2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis.» European Journal Of Gastroenterology And Hepatology 15, 697-698. 48. Sivananthan, K., and Petersen, A. «(2018). Review of Saccharomyces boulardii as a treatment option in IBD.» Immunopharmacology And Immunotoxicology 40, 465-475. 49. Tang, H., Wu, H., Mao, J., Zhu, L., Li, N., and Wang, Y. «(2014). Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis.» 11Th IEEE International Conference On Control And Automation (ICCA). 50. Zhou, W. «(2017). Saccharomyces boulardii powder combined with mesalazine for treatment of active ulcerative colitis: Curative effect and impact on fecal calprotectin and serum inflammatory factors.» World Chinese Journal Of Digestology 25, 2065.
TD – Traveler’s diarrhea prevention	I	40. Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. «Prevención of traveller’s diarrhea: comparison of different non-antibiotic preparations.» Travel Med Int 11 (1989): 9-17. 41. Kollaritsch, H., H. Holst, P. Grobara, and G. Wiedermann. «Prophylaxis of traveller’s diarrhoea with Saccharomyces boulardii.» Fortschr Med 111 (1993): 152-156. (Article in German) 42. McFarland, L. V. «Meta-analysis of probiotics for the prevention of traveler’s diarrhea.» Travel medicine and infectious disease 5.2 (2007): 97-105.

Florastor®

Florastor®
🌾

Saccharomyces boulardii lyo CNCM I-745

Capsula
Sachet

5B/Capsula
5B/sachet

1-2 Capsula
1-2 sachets

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	37. Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. «Prophylactic Saccharomyces Boulardii in the Prevención of Antibiotic-associated Diarrhea: A Prospective Study.» Medical Science Monitor 12.4 (2006): PI19-22. 38. Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. «The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of HighâDose Vancomycin Combined WithSaccharomyces Boulardii.» Clinical Infectious Diseases 31.4 (2000): 1012-017.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	I	8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. «Probiotics for the Prevención of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.» Annals of Internal Medicine 157.12 (2012): 878 9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. «Is Primary Prevención of Clostridium Difficile Infection Possible with Specific Probiotics?» International Journal of Infectious Diseases 6.11 (2012): E786-792. 38. Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. «The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of HighâDose Vancomycin Combined WithSaccharomyces Boulardii.» Clinical Infectious Diseases 31.4 (2000): 1012-017. 39. Mcfarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. «A Randomized Placebo-controlled Trial of Saccharomyces Boulardii in Combination with Standard Antibiotics for Clostridium Difficile Disease.» JAMA: The Journal of the American Medical Association 271.24 (1994): 1913-918. 51. Flatley EA, Wilde AM, Nailor MD. «Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.» J Gastrointestin Liver Dis. 2015;24(1):21–24
HP – Helicobacter pylori – Adjunct to standard eradication therapy	I	44. Song, M. J., D.I Park, J.H. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, and B.I. Kim. «The Effect of Probiotics and Mucoprotective Agents on PPI‐Based Triple Therapy for Eradication of Helicobacter pylori.» Helicobacter 15.3 (2010): 206-213. 45. Szajewska, H., A. Horvath, and A. Piwowarczyk. «Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment.» Alimentary pharmacology & therapeutics 32.9 (2010): 1069-1079. 46. Cindoruk, M., G. Erkan,T. Karakan, A. Dursun, and S. Unal. «Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study.» Helicobacter 12.4 (2007): 309-316.
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar	III	43. Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. «Saccharomyces boulardii in maintenance treatment of Crohn’s disease.» Digestive diseases and sciences 45.7 (2000): 1462-1464. 47. Guslandi, M., Giollo, P., and Testoni, P. «(2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis.» European Journal Of Gastroenterology And Hepatology 15, 697-698. 48. Sivananthan, K., and Petersen, A. «(2018). Review of Saccharomyces boulardii as a treatment option in IBD.» Immunopharmacology And Immunotoxicology 40, 465-475. 49. Tang, H., Wu, H., Mao, J., Zhu, L., Li, N., and Wang, Y. «(2014). Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis.» 11Th IEEE International Conference On Control And Automation (ICCA). 50. Zhou, W. «(2017). Saccharomyces boulardii powder combined with mesalazine for treatment of active ulcerative colitis: Curative effect and impact on fecal calprotectin and serum inflammatory factors.» World Chinese Journal Of Digestology 25, 2065.
TD – Traveler’s diarrhea prevention	I	40. Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. «Prevención of traveller’s diarrhea: comparison of different non-antibiotic preparations.» Travel Med Int 11 (1989): 9-17. 41. Kollaritsch, H., H. Holst, P. Grobara, and G. Wiedermann. «Prophylaxis of traveller’s diarrhoea with Saccharomyces boulardii.» Fortschr Med 111 (1993): 152-156. (Article in German) 42. McFarland, L. V. «Meta-analysis of probiotics for the prevention of traveler’s diarrhea.» Travel medicine and infectious disease 5.2 (2007): 97-105.

Genestra Brands HMF Metabolic

Genestra Brands HMF Metabolic
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
L. plantarum CUL-66
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (II)

Capsula

50B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference)	II	54. Michael, D.R., Jack, A.A., Masetti, G. et al. «A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being.» Sci Rep 10, 4183 (2020). https://doi.org/10.1038/s41598-020-60991-7

Genestra Brands® HMF Forte

Genestra Brands® HMF Forte
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Capsula

10B/Capsula

2-3 Capsula

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

Genestra Brands® HMF IBS Relief

Genestra Brands® HMF IBS Relief
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Capsula

25B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

Genestra Brands® HMF Intensive

Genestra Brands® HMF Intensive
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Capsula

25B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II🍁	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

Genestra Brands® HMF Intensive 50

Genestra Brands® HMF Intensive 50
🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Capsula

50B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II🍁	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

Genestra Brands® HMF Intensive Powder

Genestra Brands® HMF Intensive Powder
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Powder

25B/1 scoop (1 gram)

1 scoop

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

Genestra Brands® HMF Super Powder

Genestra Brands® HMF Super Powder
❄ 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. animalis subsp. lactis CUL-34
B. bifidum CUL-20

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Powder

10B/1 scoop (1 gram)

2-3 scoops

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

GoodBelly® Probiotic Juice Drinks

GoodBelly® Probiotic Juice Drinks
🍀

L. plantarum 299v

AAD – Diarrea asociada a antibióticos – Prevención (III)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III)
IBS – Síndrome del intestino irritable (I)

Liquid

20B/serving (8 oz)

1 serving

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	III	31. Lonnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. «Intake of Lactobacillus Plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics.» Journal of Clinical Gastroenterology 44.2 (2010): 106-12.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	III	32. Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. «Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics.» Acta Anaesthesiologica Scandinavica 52.8 (2008): 1096-102. 36. Kujawa-Szewieczek, A.; Adamczak, M.; Kwiecień, K.; Dudzicz, S.; Gazda, M.; Więcek, A. «The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics.» Nutrients 2015, 7, 10179-10188
IBS – Síndrome del intestino irritable	I	33. Niedzielin, K., H. Kordecki, and B. Birkenfeld. «A Controlled, Double-blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome.» European Journal of Gastroenterology and Hepatology 13.10 (2001): 1143-147. 34. Nobaek, S., M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. «Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome.» The American Journal of Gastroenterology 95.5 (2000): 1231-238. 35. Ducrotte, P., P. D. Sawant, and V. Jayanthi. «Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome.» World Journal of Gastroenterology 18.30 (2012): 4012-018.

Materna® Opti-Lac®

L. fermentum LC40™ CECT5716

Mastitis – Mastitis en madres lactantes (tratamiento y prevención) (I)

Capsula

3B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
Mastitis – Mastitis en madres lactantes (tratamiento y prevención)	I	55. Maldonado-Lobón, Jose A et al. «Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial.» Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine vol. 10,9 (2015): 425-32. 56. Arroyo, Rebeca et al. «Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk.» Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 50,12 (2010): 1551-8. doi:10.1086/652763

Mutaflor®

Mutaflor®
❄

Echerichia coli Nissle 1917

IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I)

Capsula

2.5-25B/Capsula

1-2 Capsula

Aplicación	Nivel	Referencias
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar	I	57. Floch, Martin H. «Probiotic therapy for ulcerative colitis.» Journal of clinical gastroenterology 44.4 (2010): 237-238. 58. Henker, J., S. Müller, M.W Laass, A. Schreiner, and J. Schulze. «Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.» Zeitschrift fuer Gastroenterologie 46.09 (2008): 874-875. 59. Kruis, W., E. Schütz, P. Fric, B. Fixa, G. Judmaier, and M. Stolte. «Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.» Alimentary pharmacology & therapeutics 11.5 (1997): 853-858. 60. Kruis, W., P. Frič, J. Pokrotnieks, M. Lukáš, B. Fixa, M. Kaščák, M.A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, and C. Wolff. «Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.» Gut 53.11 (2004): 1617-1623.

Pregnancy Care Probiotic

Pregnancy Care Probiotic
🌾

L. rhamnosus R0011
L.helveticus R0052

IBS – Síndrome del intestino irritable (III)

Capsula

2B/Capsula

1-2 Capsula

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	III	68. Benes, K., A. Kretk, and Thomas A. Tompkins. «A probiotic combination for IBS. A pilot clinical study.» NutraFoods 5.1 (2006): 20-27.

Probiotic Sticks

B. longum R0175
L. helveticus R0052

M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)

Stick

3B/stick

1 stick

Aplicación	Nivel	Referencias
M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment)	II🍁	20. Huang R., H. Ning, L. Yang, C. Jia, F. Yang, G. Xu, and H. Tan. «Efficacy of Probiotics on Anxiety: A Meta-analysis of Randomized Controlled Trials.» Neuropsychiatry 7.6 (2017): 862-71. 21. Messaoudi M., R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel, and J. Cazaubiel. «Assessment of Psychotropic-like Properties of a Probiotic Formulation ( Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) in Rats and Human Subjects.» British Journal of Nutrition 105.05 (2010): 755-64. 22. Messaoudi M., N.Violle, J. Bisson, D. Desor, H. Javelot, and C. Rougeot. «Beneficial Psychological Effects of a Probiotic Formulation (Lactobacillus HelveticusR0052 AndBifidobacterium LongumR0175) in Healthy Human Volunteers.» Gut Microbes 2.4 (2011): 256-61.

Ultra Probiotic Complex by GNC

Ultra Probiotic Complex by GNC 🌾

L. acidophilus CUL-60
L. acidophilus CUL-21
B. bifidum CUL-20
B. lactis CUL-34

CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (II)
IBS – Síndrome del intestino irritable (II)

Capsula
Packet

25B/ 50B/ 75B per Capsula
25B/packet

1-2 Capsula
1-2 packets

Aplicación	Nivel	Referencias
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	II	52. Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. «Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.» International Microbiology 7.1 (2010): 59-62.
IBS – Síndrome del intestino irritable	II	53. Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. «Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study.» Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

UltraFlora® Control

UltraFlora® Control 🌾

B. animalis ssp. lactis 420 (B420™)

WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference) (I)

Capsula

10B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
WM – Weight Management (aids in reduction of body weight, body fat mass and waist circumference)	I	71. Stenman L. K., Lehtinen M.J., Meland N., Christensen J.E., Yeung N., Saarinen M.T.,Courtney M., Burcelin R., Lähdeaho M., Linros J., Apter D., Scheinin M., Kloster Smerud H, Rissanen A., and Lahtinen S.. «Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial.» EBioMedicine 13 (2016): 190-200.

UltraFlora® Balance

L. acidophilus NCFM®
B. lactis Bi-07®

IBS – Síndrome del intestino irritable (II)

Capsula

15B/Capsula

2 Capsula

Aplicación	Nivel	Referencias
IBS – Síndrome del intestino irritable	II	72. Ringel-Kulka T, Palsson OS, Maier D, et al. «Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders.» Journal of Clinical Gastroenterology. 2011;45(6):518–525

UltraFlora® Cold Support

UltraFlora® Cold Support 🌾

L plantarum HEAL9
L. paracasei 8700:2

CID – Common infectious disease – community acquired (I)

Capsula

1B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
CID – Common infectious disease – community acquired	I	73. Berggren, A., I. L. Ahrén, N. Larsson, and G. Önning. «Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections.» European journal of nutrition 50.3 (2011): 203-210. 74. Regina, B., G. Joerg, and D. Steffi. «Randomized, Double Blind and Placebo Controlled Study Using a Combination of Two Probiotic Lactobacilli to Alleviate Symptoms and Frequency of Common Cold.» Food and Nutrition Sciences 2013 (2013).

UltraFlora® Intensive Care

UltraFlora® Intensive Care 🌾

L. plantarum 299v

AAD – Diarrea asociada a antibióticos – Prevención (III)
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención (III)
IBS – Síndrome del intestino irritable (I)

Capsula

10B/Capsula

2 Capsula

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	III	31. Lonnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. «Intake of Lactobacillus Plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics.» Journal of Clinical Gastroenterology 44.2 (2010): 106-12.
CDAD – Diarrea asociada a la bacteria Clostridium difficile – Prevención	III	32. Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. «Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics.» Acta Anaesthesiologica Scandinavica 52.8 (2008): 1096-102. 36. Kujawa-Szewieczek, A.; Adamczak, M.; Kwiecień, K.; Dudzicz, S.; Gazda, M.; Więcek, A. «The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics.» Nutrients 2015, 7, 10179-10188
IBS – Síndrome del intestino irritable	I	33. Niedzielin, K., H. Kordecki, and B. Birkenfeld. «A Controlled, Double-blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome.» European Journal of Gastroenterology and Hepatology 13.10 (2001): 1143-147. 34. Nobaek, S., M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. «Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome.» The American Journal of Gastroenterology 95.5 (2000): 1231-238. 35. Ducrotte, P., P. D. Sawant, and V. Jayanthi. «Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome.» World Journal of Gastroenterology 18.30 (2012): 4012-018.

UltraFlora® Restore

UltraFlora® Restore 🌾

B. lactis Bi-07®
L. acidophilus NCFM®
B. lactis Bl-04
L. paracasei Lpc-37

AAD – Diarrea asociada a antibióticos – Prevención (I)

Capsula

20B/Capsula

1 Capsula

Aplicación	Nivel	Referencias
AAD – Diarrea asociada a antibióticos – Prevención	I	69. A.C. Ouwehand et al. «Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study.» Vaccine 32 (2014) 458–463 70. Engelbrektson A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL. «Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.» J Med Microbiol. 2009 May;58(Pt 5):663-670. doi: 10.1099/jmm.0.47615-0. PMID: 19369530.

Visbiome®

Visbiome® ❄ 🌾
This combination of strains is known as «De Simone Formulation» and is the same one listed in references that cite VSL#3 as treatment regimen

L. acidophilus DSM24735/SD5212
L. paracasei DSM24733/SD5218
L. delbrueckii subsp. bulgaricus DSM24734/SD5210
L. plantarum DSM24730/SD5209
B. longum DSM24736/SD5220
B. infantis DSM24737/SD5219
B. breve DSM24732/SD5206
S. thermophilus DSM24731/SD5207

C – Estreñimiento (II)
IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis (I)
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar (I)
LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population) (I)

Sachet

450B/sachet

1-4 sachets

Aplicación	Nivel	Referencias
C – Estreñimiento	II	75. Parkes, G. C., D. Chatoor, and A. Emmanuel. «The probiotic VSL# 3 increases scbm and reduces symptom severity scores in patients with functional constipation.» Gut 60.Suppl 1 (2011): A163-A163 86. Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, Jung KW, Koo HS, Myung SJ «Estreñimiento Research group of Korean Society of Neurogastroenterology and Motility. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Estreñimiento.» J Neurogastroenterol Motil. 2015 Jan 1;21(1):111-20. doi: 10.5056/jnm14048. PMID: 25537674; PMCID: PMC4288088.
IBD-P – Enfermedad inflamatoria intestinal – Reservoritis o pouchitis	I	77. Tursi, A., G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, and A. Gigliobianco. «Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.» Medical Science Monitor 10.11 (2004): PI126-PI131. 79. Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, and M. Campieri.»Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.» Gastroenterology 119.2 (2000): 305-309. 80. Gionchetti, P., F. Rizzello, U. Helwig, A. Venturi, K. M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli, and M. Campieri. «Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.» Gastroenterology 124.5 (2003): 1202-1209. 81. Mimura, T., F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri, and M. A. Kamm. «Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis.» Gut 53.1 (2004): 108-114.
IBD-UC – IBD – Colitis ulcerosa – Complemento de la terapia estándar	I	76. Sood, A., V. Midha, G.K. Makharia, V. Ahuja, D. Singal, P. Goswami, and R.K. Tandon. «The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis.» Clinical Gastroenterology and Hepatology 7.11 (2009): 1202-1209. 77. Tursi, A., G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, and A. Gigliobianco. «Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.» Medical Science Monitor 10.11 (2004): PI126-PI131. 78. Tursi, A., G. Brandimarte, A. Papa, A. Giglio, W. Elisei, G.M. Giorgetti, G. Forti, S. Morini, C. Hassan, M.A. Pistoia, and M.E. Modeo. «Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study.» The American Journal of Gastroenterology 105.10 (2010): 2218-2227.
LH – Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population)	I	82. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol. 2012;107:1043–1050. 83. Shukla S., Shukla A., Mehboob S., et al. «Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy.» Alimen Pharmacol Ther. 2011;33:662–671. 84. Mittal, V.V. et al. «A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.» European Journal of Gastroenterology and Hepatology. 2011, 23:725–732 85. Lunia, M.K. et al.»Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial.» Clinical Gastroenterology and Hepatology. 2014 Jun;12(6):1003-8 87. Duseja, Ajay et al.: «High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study.» BMJ open gastroenterology vol. 6,1 e000315. 7 Aug. 2019, doi:10.1136/bmjgast-2019-000315 88. Román, Eva et al.: «Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial.» Hepatology communications vol. 3,5 632-645. 12 Mar. 2019, doi:10.1002/hep4.1325

Yakult

Yakult
🍀❄

L.casei Shirota

C – Estreñimiento (I)
CID – Common infectious disease – community acquired (I)
M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment) (II)

Bottle

8B/bottle (80ml)

Aplicación	Nivel	Referencias
C – Estreñimiento	I	200. Koebnick, C., Wagner, I., Leitzmann, P., Stern, U., and Zunft, H. (2003). Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 17, 655-659. 201. Tilley, L., Keppens, K., Kushiro, A., Takada, T., Sakai, T., Vaneechoutte, M., and Degeest, B. (2014). A probiotic fermented milk drink containing Lactobacillus casei strain Shirota improves stool consistency of subjects with hard stools. International Journal Of Probiotics And Prebiotics 9, 23-30.
CID – Common infectious disease – community acquired	I	202. Dong, H., Rowland, I., Thomas, L., and Yaqoob, P. (2013). Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers. European Journal Of Nutrition 52, 1853-1863. 203. Gleeson, M., Bishop, N., Oliveira, M., and Tauler, P. (2011). Daily probiotic’s (Lactobacillus casei Shirota) reduction of infection incidence in athletes. International Journal Of Sport Nutrition And Exercise Metabolism 21, 55-64. 204. Ivory, K., Chambers, S., Pin, C., Prieto, E., Arqués, J., and Nicoletti, C. (2008). Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clinical & Experimental Allergy 38, 1282-1289. 205. Nagao, F., Nakayama, M., Muto, T., and Okumura, K. (2000). Effects of a Fermented Milk Drink Containing Lactobacillus casei Strain Shirota on the Immune System in Healthy Human Subjects. Bioscience, Biotechnology And Biochemistry 64, 2706-2708.
M/A – Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment)	II	206. Rao A.V., Bested A.C, Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., and Logan A.C. «A Randomized, Double-blind, Placebo-controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome.» Gut Pathogens 1.1 (2009): 6. 207. Kato-Kataoka A., Nishida K., Takada M., Suda K., Kawai M., Shimizu K., Kushiro A., Hoshi R., Watanabe O., Igarashi T., Miyazaki K., Kuwano Y., and Rokutan K. «Fermented Milk Containing Lactobacillus Casei Strain Shirota Prevents the Onset of Physical Symptoms in Medical Students under Academic Examination Stress.» Beneficial Microbes 7.2 (2016): 153-56.

EXENCIÓN DE RESPONSABILIDAD *

Las afirmaciones realizadas en relación con los productos enumerados aquí no han sido evaluadas por la Administración de Alimentos y Medicamentos ni por el Ministerio de Sanidad de Canadá (a menos que se indique lo contrario).

Estos productos no están destinados a diagnosticar, tratar, curar o prevenir ninguna enfermedad. Los productos, servicios, información y otros contenidos que se ofrecen en este sitio, incluida la información que puede proporcionarse en este sitio directamente o mediante enlaces a sitios web de terceros, se proporcionan únicamente con fines informativos.

Por favor, consulte con un médico u otro profesional de la salud sobre cualquier cuestión médica o relacionada con la salud. Las indicaciones de uso del fabricante se encuentran en las etiquetas de los productos. Esta tabla refleja la evidencia publicada disponible hasta la fecha. No representa la aprobación de ningún producto específico. El trabajo en esta guía se realiza de forma independiente y sin conflictos financieros. Para minimizar el sesgo, los esfuerzos de publicación y distribución se coordinan a través de la Alianza para la Educación sobre Probióticos (AEProbio).

Estamos agradecidos por la subvención de publicación sin restricciones que la AEProbio está proporcionando para los esfuerzos continuos para traducir la ciencia en forma clínicamente aplicable.